Active Pharmaceutical Ingredients (API) are portions of any active drug, depending on the drug’s administered dosage, the reactions and therapeutic results. Certain drugs are comprised of more than one kind of active ingredient. API drug manufacturing, storage and packaging is subject to Current Good Manufacturing Process (cGMP) regulations enforced by the U.S. FDA, EMEA and other international regulatory agencies.
The global active pharmaceutical ingredients market report estimates the market size (Revenue US$ million – 2014 to 2021) for key market segments based on the API (biological, chemical), Drug (branded, generic, OTC), manufacturing (in-house, outsourcing or contact-based), therapeutic area (diabetes, cardiovascular, CNS, NSAIDs, oncology, musculoskeletal drugs, etc.), and forecasts growth trends (CAGR% – 2017 to 2021).
By manufacturing type, in-house API manufacturing segment contributed to the highest market share of the global active pharmaceutical ingredients market, while by therapeutic area, cardiovascular drug APIs segment accounted for the largest share of the global market.
The global active pharmaceutical ingredients market segmentation is based on geography (regional and country based). The global active pharmaceutical ingredients market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global active pharmaceutical ingredients market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
The major players profiled in the report include Boehringer Ingelheim Group, Cambrex Corporation, Dr. Reddy’s Laboratories, Ltd., BASF SE, Hospira, Inc., Lonza Group, Mylan, Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Actavis plc, and Wuxi Apptec.